Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

Name: Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC
Uploaded: 2014-11-01T07:59:00.000Z
Description: David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

November 1, 2014

David Spigel, MD

Video

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.

The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.

<<<